CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET REPORT 2017-2027 : Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs

がん治療用チェックポイント阻害薬の世界市場2017-2027

◆タイトル:CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET REPORT 2017-2027 : Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs
◆商品コード:VGAIN712016
◆調査・発行会社:visiongain
◆発行日:2017年10月
◆ページ数:139
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、がん治療用チェックポイント阻害薬の世界市場について調査・分析し、がん治療用チェックポイント阻害薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・がん治療用チェックポイント阻害薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・がん治療用チェックポイント阻害薬の世界市場:セグメント別市場分析
・がん治療用チェックポイント阻害薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Where is the Checkpoint Inhibitors for Treating Cancer market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 139-page report provides 96 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Checkpoint Inhibitors for Treating Cancer market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 3 submarkets and 7 Drugs in the report at a global level, as well as profiles for 19 pipeline drug candidates

Global Checkpoint Inhibitors for Treating Cancer Market by Type
• PD-1 Inhibitors
• CLTA-4 Inhibitors
• Pipeline Drugs

Global Checkpoint Inhibitors for Treating Cancer Market by Drug
• Opdivo (nivolumab)
• Keytruda (pembrolizumab)
• Yervoy (ipilimumab)
• Tecentriq (Atezolizumab)
• Imfinizi (Durvalumab)
• Bavencio – Avelumab – (MSB0010718C)
• Tremelimumab (CP-675,206)

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 8 major regional/national markets:
• The US
• Japan
• Germany
• The UK
• Italy
• France
• Spain
• Asia-Pacific

The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, the US, the UK and the APAC region in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth
Overall world revenue for Checkpoint Inhibitors for Treating Cancer will surpass $7.6bn in 2017, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Checkpoint Inhibitors for Treating Cancer Market report helps you
In summary, our 139-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Checkpoint Inhibitors for Treating Cancer market, with forecasts for 3 submarkets and 7 Drugs, each forecasted at a global level – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 8 key regional and national markets – See forecasts for the Checkpoint Inhibitors for Treating Cancer in Asia-Pacific, the US, Germany, France, the UK, Italy, France, and Japan,
• What stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market – including company profiles for some of the major companies involved in the Checkpoint Inhibitors for Treating Cancer market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain’s study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer market and leading companies. You will find data, trends and predictions.

Get our report today Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

【レポートの目次】

1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2016
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2017-2027 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2016
3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) – Merck & Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2016
3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2017-2027
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2016
4.2 The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2017-2027
4.3 Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2017-2027
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2017-2027
4.3.2 The PD-1 Inhibitors Submarket Forecast 2017-2027
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
5.1 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2017-2027
5.2 World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2017-2027
5.2.1 How Will Regional Market Shares Change to 2027?
5.3 The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4 The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.4.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.5 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027
5.6 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2017-2027

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2017-2027
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Tecentriq (Atezolizumab)
6.1.2 Imfinizi (Durvalumab)
6.1.3 Bavencio – Avelumab – (MSB0010718C) – Merck KGaA/Pfizer
6.1.4 Pidilizumab (CT-011) – CureTech Ltd
6.1.5 AMP-224 – GSK/Amplimmune
6.1.6 TSR-042 – TESARO Bio/AnaptysBio
6.1.7 AMP-514 (MEDI0680) – AstraZeneca/MedImmune
6.1.8 REGN2810 – Regeneron/Sanofi
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) – AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 – Bristol-Myers Squibb
6.3.3 IMP701 – Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 – Curis Inc/Aurigene Discovery Technologies
6.6.2 IDO and TDO Inhibitors
6.6.2.1 Indoximod (NLG-9189) – NewLink Genetics
6.6.2.2 NLG919 – NewLink Genetics
6.6.2.3 INCB024360 – Incyte/Roche
6.6.3 A2aR Inhibitors
6.6.3.1 HTL-1071 – AstraZeneca/Heptares
6.6.4 Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027
7.2 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.2.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
7.2.2 Pricing of the Treatments Will Attract Companies
7.2.3 Cost of Treatment Will Restrain Market Access
7.2.4 Side Effects May Prohibit Growth
7.3 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.3.1 Biomarkers Pave the Way for Optimum Utility
7.3.2 Combination Therapies Are Achieving Superior Results
7.3.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.3.4 Crowding of the Market with Similar Products

8. Conclusions
8.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
8.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2027
8.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2017-2027: The US and EU Will Retain Their Lead
8.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form

List of Figures
Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2016
Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2013-2016
Figure 3.2 Yervoy Forecast, Revenue ($bn), 2016-2027
Figure 3.3 Opdivo Forecast, Revenue ($bn), 2016-2027
Figure 3.4 Keytruda Forecast, Revenue ($bn),2016-2027
Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2016
Figure 3.6 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2017
Figure 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2016
Figure 4.2 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), 2016-2027
Figure 4.3 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2016
Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2016-2027
Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2016-2027
Figure 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2022
Figure 4.7 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2027
Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares (%), 2016
Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), 2016-2027
Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2022
Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2027
Figure 5.5 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.6 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.7 EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country (%), 2016
Figure 5.8 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes ($bn), 2016-2027
Figure 5.9 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.10 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2017-2027
Figure 5.11 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.12 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.13 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027

Figure 5.14 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 5.15 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2016-2027
Figure 6.1 Tecentriq Forecast: Revenue ($bn), 2016-2027
Figure 6.2 Imfinizi Forecast: Revenue ($bn), 2016-2027
Figure 6.3 Bavencio Forecast: Revenue ($bn), 2016-2027
Figure 6.4 Tremelimumab Forecast: Revenue ($bn), 2016-2027
Figure 8.1 Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2016-2027
Figure 8.2 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2016, 2018, 2022, and 2027

List of Tables
Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2016
Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2013-2016
Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2022-2027
Table 3.8 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2016
Table 3.9 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2017
Table 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2016
Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2016
Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2017
Table 4.4 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2016-2022
Table 4.5 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2022-2027
Table 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2016
Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2016-2022
Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2016-2022
Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 4.11 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2016-2022
Table 4.12 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2022-2027
Table 4.13 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market,2017-2027
Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2016
Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%),2016-2022
Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2022-2027
Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2016-2022
Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2022-2027
Table 5.6 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.7 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.8 EU Market Shares (%), 2016-2022
Table 5.9 EU Market Shares (%), 2022-2027
Table 5.10 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.11 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.12 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.13 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.14 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.15 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.16 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.17 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.18 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.19 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2016-2022
Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 5.24 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2017-2022
Table 5.25 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2022-2027
Table 6.1 Selected Combination Therapies for Atezolizumab, 2016
Table 6.2 Tecentriq Forecast: Revenue ($bn), 2017-2022
Table 6.3 TecentriqForecast: Revenue ($bn), 2022-2027
Table 6.4 Imfinizi Forecast: Revenue ($bn), 2017-2022
Table 6.5 Imfinizi Forecast: Revenue ($bn), 2022-2027
Table 6.6 Bavencio Forecast: Revenue ($bn), 2016-2022
Table 6.7 Bavencio Forecast: Revenue ($bn), 2022-2027
Table 6.8 Tremelimumab Forecast: Revenue ($bn), 2016-2027
Table 6.9 Tremelimumab Forecast: Revenue ($bn), 2022-2027
Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2016
Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 8.1 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2018, 2022, and 2027
Table 8.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2018, 2022, and 2027

★調査レポート[がん治療用チェックポイント阻害薬の世界市場2017-2027] ( CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET REPORT 2017-2027 : Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs / VGAIN712016) 販売に関する免責事項
[がん治療用チェックポイント阻害薬の世界市場2017-2027] ( CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET REPORT 2017-2027 : Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs / VGAIN712016) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆